Persistent COVID-19 Registry in Navarre.
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorFundacion Miguel Servet
About this trial
The goal of this observational study is to deepen our understanding of long COVID by determining the prevalence of the main complications and medium- to long-term sequelae of COVID-19 in Navarre.
Sociodemographic variables such as age, sex, ethnicity, smoking history, and comorbidities will be collected, as well as clinical and disease management variables such as persistent COVID-19 symptoms at 3 months, all with the aim of characterizing patients with long COVID.
All patient data will be collected in a single visit.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
History of confirmed SARS-CoV-2 infection
Presentation of symptoms that have persisted for more than 3 months after SARS-CoV-2 infection
The patient reports any of the symptoms listed in the clinical assessment questionnaire or checklist.
Disqualifiers
The symptom(s) referred to already existed prior to acute SARS-CoV-2 infection.
Trial population
Patients seen in the Internal Medicine outpatient clinic who have been referred by primary care teams or other medical services.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
200 Participants
are grouped into 1 trial groupGroup A: Patients diagnosed with long COVID
Trial outcomes
Primary outcomes
1
Describe the demographic, clinical and analytical characteristics of patients with persistent COVID in our setting.
The following sociodemographic variables: age, gender, ethnicity, smoking history, and comorbidities, and analytical variables, will be collected.
Time frame
Basal visit2
Establish the prevalence of different symptoms, complications and/or medium- to long-term sequelae of COVID-19 in Navarre.
6\) Diagnosis of: * Thromboembolic disease (deep vein thrombosis and/or pulmonary embolism at discharge and/or pulmonary thromboembolism). * Acute cerebrovascular accident (embolic and/or atherothrombotic: referred to as stroke/ACVA/TIA/cerebral infarction) during admission for COVID-19. Establish assessment criteria by Internal Medicine and/or Neurology. * Peripheral arterial ischaemic event during admission for COVID-19 * Acute complication of pre-existing coronary artery disease and/or acute coronary event (acute coronary syndrome or ACS). * suspicion and/or diagnosis of myopericarditis during admission. * criteria for acute hepatitis (GOT and/or GPT \>5 times normal range (\>200 during admission) and/or liver dysfunction (Br \>3 mg/dl).
Time frame
Basal visitSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov